The clinical utility of apoB versus LDL-C/non-HDL-C

This is one of the sharpest statements of the ApoB case, from a group that includes its most prominent champion. The question it answers: does measuring ApoB actually change what you’d do, beyond LDL-C and non-HDL-C?

The argument hinges on discordance. ApoB counts atherogenic particles; LDL-C measures cholesterol mass — and the two come apart in people with type 2 diabetes, high triglycerides, or obesity, whose LDL particles run small and cholesterol-poor. In those patients a reassuring LDL-C can sit atop a dangerously high particle count, and the evidence — discordance analyses, Mendelian randomization, post-hoc trial data — shows risk follows ApoB, not the cholesterol number.

The practical takeaway is targeted testing: measure ApoB in metabolically high-risk patients, where it reveals risk the standard panel hides. The resistance is guideline conservatism favoring LDL-C for simplicity and cost, plus lab concerns about assay standardization.

We rate the evidence strong: though a review, it rests on consistent findings across observational, genetic, and trial-derived data, which together support causal inference. Its clinical significance is very high — shifting the primary marker to ApoB would reclassify risk for the enormous diabetic and metabolic-syndrome population, catching events that LDL-guided care misses.